Ypsomed Holding AG (LON:0QLQ)
London · Delayed Price · Currency is GBP · Price in CHF | Market Cap | 4.20B -4.1% |
| Revenue (ttm) | 690.14M -2.4% |
| Net Income | 209.53M +153.6% |
| EPS | 15.39 +154.3% |
| Shares Out | n/a |
| PE Ratio | 20.03 |
| Forward PE | 25.32 |
| Dividend | 2.03 (0.61%) |
| Ex-Dividend Date | Jul 4, 2025 |
| Volume | 202 |
| Open | 335.80 |
| Previous Close | 335.61 |
| Day's Range | 335.80 - 340.40 |
| 52-Week Range | 263.50 - 440.00 |
| Beta | 0.74 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 20, 2026 |
About Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication in Switzerland, Europe, North America, and internationally. The company offers various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other related services. It offers contract manufacturing of infusion sets and reservoirs. The company markets its products to hospitals, doctors, pharmacies and patients via subsidiaries and distributors. Ypsomed Hold... [Read more]
Financial Performance
In fiscal year 2026, Ypsomed Holding AG's revenue was 730.98 million, a decrease of -2.39% compared to the previous year's 748.87 million. Earnings were 221.93 million, an increase of 153.62%.
Financial numbers in CHF Financial StatementsNews
Ypsomed Holding AG Transcript: H2 25/26
Achieved record sales and EBIT, driven by strong growth in Delivery Systems and successful transformation into a focused, high-margin business. Outlook remains robust with double-digit sales growth and margin targets, supported by innovation, operational excellence, and global expansion.
Ypsomed Holding AG Annual report: H2 2026
Ypsomed Holding AG has published its H2 2026 annual report on May 20, 2026.
Ypsomed Holding AG Slides: H2 2026
Ypsomed Holding AG has posted slides in relation to its H2 2026 quarterly earnings report, which was published on May 20, 2026.
Ypsomed Holding AG Earnings release: H2 2026
Ypsomed Holding AG released its H2 2026 earnings on May 20, 2026, summarizing the period's financial results.
Ypsomed Holding AG Transcript: 44th Annual J.P. Morgan Healthcare Conference
Management outlined a strategic shift to a pure-play injection device business, driven by strong growth in injectables, biosimilars, and GLP-1 therapies. Financial targets include doubling sales by 2030, maintaining high margins, and expanding global production, with risks mainly in execution and market volatility.
Ypsomed Holding AG Slides: 44th Annual J.P. Morgan Healthcare Conference
Ypsomed Holding AG has posted slides in relation to its latest quarterly earnings report, which was published on January 15, 2026.
Ypsomed Holding AG Transcript: H1 25/26
Strong H1 results driven by 21% core sales growth, 32.4% EBIT margin, and strategic focus on B2B injection devices. Guidance for 20% annual sales growth and >30% EBIT margin is confirmed, with major capacity expansion and innovation underway.
Ypsomed Holding AG Quarterly report: H1 2026
Ypsomed Holding AG has published its H1 2026 quarterly earnings report on November 12, 2025.
Ypsomed Holding AG Slides: H1 2026
Ypsomed Holding AG has posted slides in relation to its H1 2026 quarterly earnings report, which was published on November 12, 2025.
Ypsomed Holding AG Slides: FY 2025
Ypsomed Holding AG has posted slides in relation to its FY 2025 quarterly earnings report, which was published on September 29, 2025.